Weekly shot · weight loss · in phase 3 trials
A weekly shot that helped people in a trial lose about a fifth of their weight. It is not approved anywhere yet. Whether you are curious, in a trial, or already on it, here is what helps.

Status as of November 17, 2026. For information only, not medical advice: read the medical disclaimer.
Where are you with Eloralintide?
Good place to start. Here is what we would want to know before deciding, in plain words.
Eloralintide is still in trials. The only legal way to get it is to join a trial. The first big phase 3 trial is not expected to finish before 2028, so there is no launch date.
In the main trial, people on 9 mg lost about a fifth of their weight over 48 weeks. People on placebo lost almost nothing (0.4%).
On 9 mg, about 1 in 3 felt sick (1 in 7 on placebo) and about 4 in 10 felt tired (1 in 8 on placebo). On the lowest two doses, nausea was about as common as on placebo.
In one small study, 4 people had low mood. The 3 who stopped the drug felt better within 2 to 4 days. Larger trials have not yet said whether this happens more than on placebo.
Coming Pick your questions and print them as one page.
Eloralintide has no label, so there are no official rules for starting it. Here is what the trials saw, and what the label of a different approved drug advises.
There is no approved eloralintide dose. If you join a trial, the trial team decides your dose and how it changes. The doses on this page are what the trials tested, not a plan for you.
In trials, stomach side effects happened mainly while doses were being raised. In phase 2, raising the dose more slowly meant fewer stomach effects and less tiredness. This describes the trials, not a plan for you.
Weight, waist and a photo on day one make it much easier to see change later.
Coming A progress log that stays only on your device.
You’re on it. Here’s how to feel better day to day, and how to tell if it’s working.
Tiredness was one of the side effects that rose most with dose in phase 2, in up to about 46% of people on some doses (12% on placebo). Mention it to your doctor or trial team.
Because of the small mood signal in early trials, note how you feel each week. If you feel low, tell your doctor or trial team. No judgement, it is useful for them to know.
We have not seen a week-by-week weight curve from the main trial, only the result at week 48.
No judgement. We won’t tell you where to buy or how much to take. Trial results describe Lilly’s study drug, not products sold online under the same name. No trial has tested those in people, so nobody knows what to expect. These steps lower the risk whatever you use:
Most side effects are mild and fade. A few need a call today, and a few need help right now. Here is how to tell them apart.
Emergency: call 911 (or your local emergency number). Possible overdose or wrong amount: Poison Help, 1-800-222-1222, free and open 24 hours. Report a bad reaction to the FDA through MedWatch.
Tell your doctor or trial team soon. In a small study, people whose mood dropped felt better within 2 to 4 days of stopping the drug.
Every number below says what kind of study it came from. Bracketed numbers point to the sources listed at the end.
In healthy adults given a single 12 mg shot, weight was down 4.4% four weeks later. On placebo it went up 0.6%.
Small human study[6]In a study of 100 adults, the 12 mg group lost 11.3% more than placebo after 12 weeks. About 1 in 5 people on the drug had less appetite (19%), and about 1 in 8 had headaches (12%).
Small human study[4]In a trial with tirzepatide, stomach side effects happened mainly while doses were being raised. In phase 2, raising the dose more slowly meant fewer stomach effects and less tiredness (Lilly release, 2025-11-06).
Company press releaseLilly press release, 2026-09-30In the main trial, the 9 mg group lost 20.1% of their weight on average, about 21 kg. The placebo group lost 0.4%.
Human randomised trial[3]Averages from trials, not a forecast for you. Each step comes from a different trial with different people and doses, so the steps are not one curve. Sources: days 3 to 6 and week 4[6]; levels through the week and week 12[4]; step-up, Lilly releases 2025-11-06 and 2026-09-30; week 48[3] and Lilly release 2025-11-06.
We have not seen a week-by-week weight curve from the phase 2 trial, only the result at week 48. The full paper may have one; we have read only the abstract.
What people in the trial said. In exit interviews from phase 2, 74% said they had fewer cravings and 52% said they had less "food noise". Of those who drank alcohol at the start, 41% said they drank less (Lilly release, 2026-11-14). Lilly did not say how many people were interviewed.
We have not added advice on what to eat when your appetite drops. We will only add it from published guidance, with the source named.
In phase 2, on 9 mg about 1 in 3 people had nausea, vs about 1 in 7 on placebo (33% vs 14%). About 4 in 10 felt tired, vs about 1 in 8 on placebo (43% vs 12%). On 6 mg, about 2 in 3 had nausea (64%). On 1 mg and 3 mg, nausea was about as common as on placebo (11% and 13%). Source: Lancet 2025[3]; full tables in side effects reported in trials.
Mood. In the 12-week phase 1b study, 3 people had low mood and 1 had a longer-lasting low mood. The 3 on 12 mg stopped the drug, and their mood got better within 2 to 4 days[4]. Larger trials have not yet said whether this happens more often than on placebo.
Diarrhoea, nausea and vomiting can make you lose fluids. The guide says drinking fluids helps lower the chance of dehydration, which can harm your kidneys.
The guide says to tell your provider about stomach problems that are severe or will not go away.
The guide says not to share a pen or needles, even with a new needle. You could pass on or catch a serious infection.
The guide says food can get into the lungs during procedures that put you to sleep. Tell all your providers before any surgery.
These tips come from the Zepbound (tirzepatide) Medication Guide[1], revised 08/2026. Tirzepatide is an approved weight-loss medicine that works on different hormones, and Lilly is testing it together with eloralintide. Eloralintide has no label of its own, and no study has tested these tips with eloralintide. Nothing here is advice to change a dose.
These warning signs come from the Zepbound (tirzepatide) Medication Guide[1], revised 08/2026, the label of an approved medicine that works differently. Eloralintide has no label of its own, so these are not eloralintide warnings.
These are ways to keep a record. They are not targets, and they do not replace checks by your doctor or trial team.
Dose questions belong with your prescriber or trial team. This page lists trial doses only, and none of them is a dose for you.
Eloralintide is a long-acting amylin receptor agonist developed by Eli Lilly under the code name LY3841136[6]. It is given as a once-weekly injection under the skin in trials. It is investigational: Lilly calls it investigational (Lilly press release, 2026-11-14), and phase 3 trials started in December 2025[5].
Phase 3 trials registered, about 11,730 people planned (ClinicalTrials.gov, 2026-11-17)
Trial registryHighest rung reached: a phase 2 human RCT (Lancet 2025). Eight phase 3 trials are running and none has reported.
Elora, LY3841136 and misspellings. "Elora" and "Elora peptide" are community short names for eloralintide. LY3841136 is Lilly's code name. "Eloranlintide" and "loralintide" are common misspellings of the same drug.
Structure in plain words. Eloralintide is a modified copy of the hormone amylin. Its main chain has 37 amino acids, three of which are not found in natural proteins. A more stable chemical bridge replaces the natural amylin's sulphur bridge, and a fatty acid is attached at position 26 so that the drug binds to albumin in the blood, which makes it last longer (full text PMC12640043)[6].
Half-life. After a single dose, the half-life was 310 to 366 hours (12.9 to 15.3 days) across doses from 0.04 to 12 mg, and blood levels peaked 72 to 132 hours after the injection[6]. With weekly dosing, the ratio between peak and trough levels at steady state was 1.28 to 1.38, meaning levels stayed fairly even through the week[4].
Amylin is released from the pancreas together with insulin. It slows stomach emptying, lowers glucagon and acts on the brain to bring on fullness[7]. Eloralintide is built to act mainly on one amylin receptor, called AMY1R. The table shows which findings come from cells, animals or people.
| Finding | Where it was shown | Source |
|---|---|---|
| Activates the human AMY1R receptor 12 times more than the calcitonin receptor and 11 times more than AMY3R | Cells | [6] |
| In rat cells the pattern differs: AMY1R and AMY3R were both activated more than the calcitonin receptor | Cells (rat) | [6] |
| Less taste avoidance (an animal sign of feeling unwell) than cagrilintide, p < 0.05, in a Lilly-run study | Lean rats | [6] |
| Lower food intake and body weight, mostly from fat loss | Rats with diet-induced obesity | [6] |
| Weight loss that grows with dose | People: phase 1 and phase 2 trials | [3] |
Reviewers suggest that acting mainly on the amylin receptor, and less on the calcitonin receptor, may affect how well the drug is tolerated. This is a hypothesis; no human trial has tested it[8]. Because receptor selectivity differs between rats and people, rat results cannot be carried straight over to humans.
Phase 1, single doses. In 48 healthy adults given one dose of 0.04 to 12 mg, weight four weeks later had changed by −2.5% on 4 mg and −4.4% on 12 mg, vs +0.6% on placebo[6][9].
Phase 1b, 12 weeks of weekly doses. In 100 adults with overweight or obesity, doses were given at a fixed level with no step-up. Weight change vs placebo at week 12 was −2.6% (1.2 mg), −8.9% (3 mg), −8.5% (6 mg) and −11.3% (12 mg)[4].
Phase 2, 48 weeks, 263 people. The main trial enrolled adults with a BMI of 30 or more, or 27 or more with a weight-related condition, and no type 2 diabetes, at 46 US sites. Average starting weight was 109.1 kg[3][10]. The weight figures below use the efficacy estimand, which assumes everyone stayed on treatment. The figure that counts people who stopped (treatment-regimen estimand) is in the full paper, which we have not yet read.
| Arm (once weekly) | n | Weight change at 48 weeks | 95% CI | Nausea | Fatigue |
|---|---|---|---|---|---|
| 1 mg | 28 | −9.5% | −12.6 to −6.3 | 11% | 0% |
| 3 mg | 24 | −12.4% | −14.9 to −9.8 | 13% | 13% |
| 6 mg | 28 | −17.6% | −20.7 to −14.5 | 64% | 29% |
| 9 mg | 54 | −20.1% | −22.7 to −17.5 | 33% | 43% |
| 6 → 9 mg | 24 | −19.9% | −22.7 to −17.0 | 54% | 46% |
| 3 → 6 → 9 mg | 52 | −16.4% | −18.6 to −14.1 | 25% | 21% |
| Placebo | 53 | −0.4% | −2.2 to 1.4 | 14% | 12% |
Weight change: exact values from Lilly's release (2025-11-06); 95% confidence intervals from the Lancet abstract[3], which rounds the means. Nausea and fatigue: Lancet abstract. Efficacy estimand.
Scale: 0–20.1%
Bars show weight lost. Source: Lancet 2025[3]; exact values from Lilly's release, 2025-11-06. On 9 mg the mean loss was 21.3 kg vs 0.2 kg on placebo (Lilly release).
Who ran the trials. All published eloralintide trials were funded by Lilly. In the phase 1 paper, every author was a Lilly employee[6].
Phase 2b with tirzepatide (EloraTZP). Lilly tested eloralintide alone and together with tirzepatide (given as separate injections) in 367 people with obesity and type 2 diabetes for 48 weeks. The results come from a company press release (2026-09-30, presented at EASD) and had not appeared in a journal by 2026-11-17[11].
| Arm | Weight change | HbA1c change (points) |
|---|---|---|
| Eloralintide 3 mg + tirzepatide 5 mg | −13.2% | −2.2 |
| Eloralintide 6 mg + tirzepatide 5 mg | −19.4% | −2.7 |
| Eloralintide 6 mg + tirzepatide 10 mg | −19.9% | −2.6 |
| Eloralintide 9 mg + tirzepatide 15 mg | −23.3% | −2.9 |
| Tirzepatide 15 mg alone | −14.8% | −2.4 |
| Eloralintide 3 mg alone | −8.2% | −1.1 |
| Eloralintide 6 mg alone | −12.3% | −1.4 |
| Eloralintide 9 mg alone | −11.1% | −1.3 |
| Placebo | −3.0% | −0.3 |
EloraTZP phase 2b, 48 weeks, efficacy estimand. Source: Lilly press release, 2026-09-30 (company press release, not peer-reviewed); trial record[11].
What people in phase 2 said afterwards. In exit interviews from the phase 2 trial, 74% reported fewer cravings, 52% reported less "food noise", and 41% of those who drank alcohol at the start said they drank less (Lilly press release, 2026-11-14, ObesityWeek poster). These are company-reported qualitative interviews, and Lilly did not say how many people were interviewed.
What independent reviews say. A network meta-analysis of six trials (4,642 people) estimated −18.01% vs placebo for high-dose eloralintide. The authors call the evidence sparse and low-certainty, and the comparison is across trials of different lengths[12]. A narrative review describes its early side-effect profile, including fatigue, headache and loss of appetite, as distinct from other drugs in the class[13].
| Trial and source | Dose tested and how it was reached | Weeks | Weight change |
|---|---|---|---|
| Phase 1 single dose | One dose: 0.04, 0.12, 0.4, 1.2, 4 or 12 mgHealthy adults, n=48 | 4 (follow-up) | 4 mg −2.5%; 12 mg −4.4% vs placebo +0.6% |
| Phase 1b | 1.2 mgNo escalation | 12 | −2.6% vs placebo |
| Phase 1b | 3 mgNo escalation | 12 | −8.9% vs placebo |
| Phase 1b | 6 mgNo escalation | 12 | −8.5% vs placebo |
| Phase 1b | 12 mgNo escalation | 12 | −11.3% vs placebo |
| Phase 2 | 1 mgFixed | 48 | −9.5% |
| Phase 2 | 3 mgFixed | 48 | −12.4% |
| Phase 2 | 6 mgFixed | 48 | −17.6% |
| Phase 2 | 9 mgFixed | 48 | −20.1% |
| Phase 2 | 9 mg6 → 9 mg | 48 | −19.9% |
| Phase 2 | 9 mg3 → 6 → 9 mg | 48 | −16.4% |
| Phase 2 | Placebo– | 48 | −0.4% |
| Phase 2b (T2D) | 3 / 6 / 9 mg aloneNot stated in the release | 48 | −8.2 / −12.3 / −11.1% |
| Phase 2b (T2D) | 3 to 9 mg + tirzepatide 5 to 15 mg (4 pairings)Separate injections | 48 | −13.2% to −23.3% |
| Phase 3 (8 trials) | Doses hidden in the registry as "Dose 1" to "Dose 4"Not public | 64 to 100 | No results yet |
All arms were once weekly, under the skin, except the single-dose phase 1 study. Phase 1b figures are placebo-adjusted; phase 2 and 2b figures use the efficacy estimand.
How many weeks each step lasted in the 6 → 9 mg and 3 → 6 → 9 mg arms is not given in the Lancet abstract or Lilly's release. There is no eloralintide "protocol" to follow; the only sourced doses are the trial arms above. Every multiple-dose trial so far gave eloralintide once a week.
This page has no vial calculator, because no eloralintide product, label or vial size exists to measure.
In phase 2, nausea and tiredness were the side effects that changed most with dose. Lilly says stomach and gut side effects and fatigue were more frequent at higher doses, lower with slower step-up, and similar to placebo on 1 mg and 3 mg (Lilly press release, 2025-11-06).
Scale: 0–64%
Source: Lancet 2025[3]. Placebo is the same 14% on every row. Fatigue figures are in the phase 2 table above (0% to 46% vs 12% on placebo).
Phase 1b side effects. Over 12 weeks, people on eloralintide reported less appetite (19%), headache (12%), fatigue (11%), diarrhoea (10%), nausea (8%) and vomiting (4%); 13% had injection-site reactions[4]. In the single-dose study, two people reported four stomach and gut events, one of them moderate vomiting[6].
Mood events in the phase 1b study. One person on 6 mg and two on 12 mg reported depressed mood, and one more on 12 mg had persistent depressive disorder. All three people on 12 mg with mood events stopped the drug, and the events resolved within 2 to 4 days[4]. The phase 2 abstract does not mention mood events, so it is not yet known whether this appears in larger trials.
Scale: 0–14.4 bpm decrease
Bars show how far average pulse fell. The paper reports no slow heart rate that caused symptoms. Source: Bhattachar 2026[4].
| Trial | Eloralintide | Comparator | Source |
|---|---|---|---|
| Phase 1b | 11 people: 5 COVID-19, 2 depressed mood, 1 each persistent depressive disorder, jaw fracture, sleepiness and decreased appetite; none for nausea, vomiting or diarrhoea | Placebo: 2 (both COVID-19) | [4] |
| Phase 2 | Not given in the abstract or release | – | [3] |
| Phase 2b (EloraTZP) | Eloralintide alone 0% to 10.8%; with tirzepatide 10.8% to 27.0% | Tirzepatide 2.9%; placebo 16.7% as reported (unusually high; not yet checked against a paper) | Lilly 2026-09-30[11] |
People who stopped because of side effects.
In the phase 2b trial, stomach and gut side effects were more frequent in the combination arms and happened mainly while doses were being stepped up (Lilly press release, 2026-09-30).
Searching "eloralintide reddit"? The figures on this page describe Lilly's study drug given under trial conditions. They tell you nothing about products sold online under the same name.
Phase 1b study of weekly doses begins at three US centres.
Bhattachar et al., DOM 2026[4] Small human studyPhase 2 published in the Lancet: up to −20.1% at 48 weeks.
Billings et al., Lancet[3] Human randomised trialENLIGHTEN-1 starts; ENLIGHTEN-3, -4 and -6 start the same month.
ClinicalTrials.gov[14] Trial registryEarliest estimated primary completion of a phase 3 trial (ENLIGHTEN-2).
ClinicalTrials.gov[5] Trial registry| Trial | Registry | Who | People | Start | Primary completion | Main endpoint |
|---|---|---|---|---|---|---|
| ENLIGHTEN-1 | [14] | Obesity or overweight, no diabetes | 1,980 | 2026-02-06 | 2028-03 | Weight change, week 64 |
| ENLIGHTEN-2 | [5] | Obesity or overweight with type 2 diabetes | 1,035 | 2025-12-15 | 2028-01 | Weight change, week 64 |
| ENLIGHTEN-3 | [17] | Moderate to severe sleep apnoea | 800 | 2026-02-10 | 2028-03 | Weight change and AHI, week 64 |
| ENLIGHTEN-4 | [18] | Knee osteoarthritis pain | 900 | 2026-02-09 | 2028-03 | Weight change and WOMAC pain, week 64 |
| ENLIGHTEN-6 | [19] | Obesity persisting on a weekly incretin drug; added on top | 900 | 2026-02-10 | 2028-06 | Weight change, week 64 |
| ENLIGHTEN-10 | [20] | Obesity, type 2 diabetes and raised heart risk | 3,000 | 2026-12 (planned) | 2029-11 | Weight change week 64; HbA1c week 36 |
| AMPLIFY-1 | [21] | Obesity, no diabetes: EloraTZP vs tirzepatide vs eloralintide vs placebo | 2,115 | 2026-12 (planned) | 2029-10 | Weight change, week 100 |
| AMPLIFY-2 | [16] | Obesity with type 2 diabetes: EloraTZP vs tirzepatide | 1,000 | 2026-10-16 | 2029-10 | Weight change, week 100 |
Read from ClinicalTrials.gov on 2026-11-17. None has posted results. Doses are hidden as "Dose 1" to "Dose 4". Dates are registry estimates.
Other registered studies have no published results yet, including phase 1 studies in Chinese[22] and Japanese participants[23], kidney and liver impairment studies[24][25], and phase 2 studies of macupatide with or without eloralintide[26][27].
No. Eloralintide is not approved by the FDA or anywhere else; Lilly calls it investigational (Lilly press release, 2026-11-14). Lilly has not given a filing date in the sources we read. The only way to receive it legally is in a clinical trial.
| Item | Status as of 2026-11-17 | Source |
|---|---|---|
| FDA approval | Not approved; investigational | Lilly press release, 2026-11-14 |
| FDA 503A bulk substances categories list | Not listed (searched the version updated 2026-05-14) | FDA categories list[28] |
| HHS draft policy on 503A peptide compounding (2026-10-30) | A draft notice with an appendix of peptides. We could not open the appendix; summaries by law firms list six peptides, and eloralintide is not one of them | Federal Register, FR Doc 2026-22192[29] |
| FDA warning letters or import alerts naming eloralintide | None found | fda.gov search, 2026-11-17 |
| Sport (WADA) | Not named. It falls under S0, non-approved substances, which are prohibited at all times | WADA 2026 Prohibited List, section S0 |
Both are amylin-based. Eloralintide acts mainly on AMY1R; cagrilintide also acts on the calcitonin receptor[6][30]. Eloralintide's single-dose half-life is 12.9 to 15.3 days; the same paper cites 6.6 to 8.1 days for cagrilintide. No human trial has compared them directly.
Both are Lilly drugs in trials. Retatrutide acts on GIP, GLP-1 and glucagon receptors. Pulse fell with dose on eloralintide[4], while heart rate rose with dose on retatrutide[31]; these come from separate trials. No trial compares or combines the two.
Lilly's own combination, EloraTZP, is covered in the trial results above. AMPLIFY-1 will compare it with each drug alone over 100 weeks[21]. No combination of the two is approved.
Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.
"Elora" is a short name for eloralintide (code name LY3841136). It is a weekly shot from Eli Lilly, made as a changed copy of amylin, a hormone that helps you feel full[6].
No. Lilly calls it investigational, which means it is still being tested (Lilly release, 2026-11-14). It is in phase 3 trials.
There is no date. Lilly has not given one in the sources we read. The first phase 3 trial is expected to reach its main result in January 2028[5].
No one can say for you. In the 48-week phase 2 trial, average weight change went from 9.5% lost on 1 mg to 20.1% lost on 9 mg. Placebo was 0.4% lost. These figures assume everyone stayed on the drug[3].
Yes. Every trial with repeat doses gave it once a week as a shot under the skin. After one shot, the level in the blood took 12.9 to 15.3 days to drop by half[6].
It might. In phase 2, tiredness went from 0% to 46% across the drug groups, vs 12% on placebo. It was more common on higher doses[3].
It is Lilly's mix of eloralintide and tirzepatide, given as two shots. In a 48-week trial in people with type 2 diabetes, the groups on both drugs lost 13.2% to 23.3% (Lilly release, 2026-09-30, not yet in a journal). Phase 3 trials have started[21].
Yes. WADA does not name it. But it has no approval anywhere, so it falls under section S0 of the 2026 Prohibited List. That section bans unapproved drugs at all times.